

Open Trials at IOR

<i>Trial</i>	<i>Sponsor</i>	<i>Type</i>	<i>Agent</i>	<i>Histology</i>	<i>Line</i>
GEIS-52 (ImmunoSARC2)	GEIS PI: E.Palmerini	Ph2 No profit	Sunitinib+ Nivolumab	In Italy: -Cohort1: only dedifferentiated chondrosarcoma subcohort -Cohort2 EMC -Cohort3 VS : closed due to interim analysis. -Cohort5 ASPS (only1 spot left) -Cohort6 CCS (1 spot left which is reserved for a patient that is already on screening)	2+
DCC-3014-01-001	Deciphera Pharmaceuticals, LLC. PI: E. Palmerini	Ph2 Profit	DCC-3014	TGCT	ArmB: 2+ (previously treated with imatinib and/or nilotinib)
DCC-3014-03-001 (MOTION) (not open yet- contract to finalize)	Deciphera Pharmaceuticals, LLC. PI: E.Palmerini	Ph3 Profit Randomized vs placebo	Vimseltinib	TGCT	Any (previously treated with anti-CSF1)

Open Trials at IOR

<i>Trial</i>	<i>Sponsor</i>	<i>Type</i>	<i>Agent</i>	<i>Histology</i>	<i>Line</i>
STRADA	ItalianSarcoma Group PI: E.Palmerini	Ph2 No Profit Randomized Open-label	Trabectedin vs Doxorubicin + DTIC	SFT	Any
ISG-MCS	ItalianSarcoma Group PI: T.Ibrahim	Ph2 No profit	Trabectedin	Mesenchymal chondrosarcoma	2+
METFORMINABONE	IOR PI: A.Longhi	Ph2 No Profit	Metformina	coorte 1) Osteosarcoma localizzato con necrosi <60% coorte 2) Osteosarcoma e Sarcoma Ewing in remissione completa dopo I ricaduta	NA
rEECur	University of Birmingham PI: T.Ibrahim	Ph3 No Profit (financed)	Carboplatin- Etoposide vs Ifosfamide	Ewing's Sarcoma and Ewing-like	2+

Open Trials at IOR

<i>Trial</i>	<i>Sponsor</i>	<i>Type</i>	<i>Agent</i>	<i>Histology</i>	<i>Line</i>
FLASH	Philogen PI: E.Palmerini	Ph2 Profit	DTIC + L19TNF vs DTIC	STS locally advanced/metastatic	3+
ISG-ARTICLE	Italian Sarcoma Group PI: T.Ibrahim	Ph2 No Profit	Trabectedin vs Gemcitabine	Leiomyosarcoma locally advanced/metastatic	2+
FIBROSARC	Philogen PI: E.Palmerini	Ph3 Profit	DOXO + L19TNF vs DOXO	STS locally advanced/metastatic	1+
ON-TRK (SIV scheduled for 12Oct22)	Bayer AG PI: T.Ibrahim	Obs. Profit	Larotrectinib	TRK fusion cancer locally advanced/metastatic	NA

Open Trials at IOR

<i>Trial</i>	<i>Sponsor</i>	<i>Type</i>	<i>Agent</i>	<i>Histology</i>	<i>Line</i>
J1S-MC-JP04 (approved by EC contract to finalize)	ELI Lilly and Company	Ph2 PI: E.Palmerini	Abemaciclib + Irinotecan + Temozolamide vs Irinotecan + Temozolamide	Ewing's Sarcoma Relapsed/refractory	2+
A5481092 (approved by EC contract to finalize)	Pfizer	Ph1/2 PI: E.Palmerini	Palbociclib + Irinotecan + Temozolamide vs Topotecan + Cyclophosphamide	Ewing's Sarcoma Relapsed/refractory	2+